Phase 2 N=46 Varenicline to Reduce Alcohol Consumption in Heavy Drinkers
Alcohol Drinking
Primary: Alcohol Consumption — 92.0; 77.3 mg/%
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=114 A Quality of Life Study of Peginterferon-Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C and Persistently Normal Alanine Transaminase (ALT) Levels
Hepatitis C, Chronic
Primary: Change From Baseline in 36-Item Short-Form Health Survey (SF-36) General Health Domain at End of Treatment (EOT) — -3.2; -3.0; -7.4; -1.2 units on a scale — p=0.647
N/A N=292 Early Detection and Intervention for the Prevention of Psychosis
Schizophrenia · Bipolar Disorder · Depression
Primary: Psychotic Symptoms — 9.2; 6.7 units on a scale — p=.0034
Phase 4 N=40 Safety and Efficacy Study of Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients
BK Virus Infection
Primary: Evidence of Reduction of BK Viruria and/or Clearance of BK Viremia — 11; 8 participants — p=0.53
Phase 1 N=47 Subcutaneous Pharmacokinetics of Belatacept
Transplantation
Primary: Maximum Observed Serum Concentration (Cmax) of Belatacept — 3.9; 6.2; 8.5; 11.1 ug/mL
Phase 2 N=21 Trial of Amitriptyline for Chronic Oral Food Refusal in Children 9 Months to 8 Years of Age
Chronic Oral Food Refusal
Primary: % Calories Taken Orally — 68.62; 76.89 change in percent kcal obtained orally
Phase 1 N=76 Adaptive Physical Activity for Chronic Stroke
Stroke
Primary: 6 Minute Walk Test (6MWT) — 189; 172; 211; 170 meters — p=<0.25
Phase 3 N=29 Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)
Epilepsy
Primary: Percentage of Subjects Who Achieved a Clinically Meaningful Reduction of Nonpsychotic Behavioral Side Effects Based on the Investigator's Overall Assessment From Study…
Phase 3 N=50 Crossover Study to Compare PK of Once Daily LCP-Tacro Tablets to Generic Tacrolimus Capsules Twice Daily.
Renal Failure
Primary: Evaluation of AUC(0-24) for Envarsus XR and IR-Tac — 251.9; 247.9 ng*hr/mL
Phase 2 N=24 Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
Advanced Nonhematological Malignancies · Non-Small Cell Lung Cancer · Small Cell Lung Cancer
Primary: Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 2 participants
Phase 2 N=132 Norovirus Bivalent-Vaccine Efficacy Study
Prevention From Norovirus Infection
Primary: Percentage of Participants With Viral AGE Clinical Illness and Fecal Virus Excretion Detected by RT-PCR OR 4-Fold Rise In Anti-GII.4 Norovirus P Particle Antibody Titer…
Phase 2 N=286 Mindfulness Based Relapse Prevention: Efficacy and Mechanisms
Substance Use Disorders
Primary: Mean Number of Alcohol and Drug Use Days Out of Past 30 — 1.44; 3.89; 4.65; 3.06 number of days out of past 30
N/A N=24 Virtual Path Planning for Image-guided Needle Interventions
Gastrointestinal Diseases · Bone Diseases · Muscular Diseases
Primary: System Usability Scale (SUS) Score as a Measure of Qualitative Clinical Usefulness — 76 Scores on a scale
Phase 2 N=55 Atorvastatin to Treat Pulmonary Sarcoidosis
Sarcoidosis, Pulmonary
Primary: The Steroid Sparing Period — 301; 257 days
Phase 4 N=445 Comparison of Increasing Doses of Tapentadol Versus a Combination of Tapentadol and Pregabalin
Low Back Pain · Neuropathic Pain
Primary: Change in the Average Pain Intensity Score for the Overall Low Back Pain on an 11-point Numeric Rating Scale (NRS-3) — -1.6; -1.7 units on a scale